March 6, 2015
Bladder carcinomas are among the more frequent and highly recurrent cancers. In spite of its obvious high impact on public health and to its increasing burden to the health budget, available therapies are still of limited efficacy. Bladder instillation of nontargeted therapeutics is rendered inefficient by dilution of the agent by urine influx and elimination of the agent by the periodic voiding of the bladder content.
Researchers at Purdue University have developed a family of artificial multivalent targeting peptides that show improved protein solubility/stability, greater binding potential, and a very high rate of uptake by tumor cells. This design is based on the strategies utilized by different bacteria, such as the therapeutically used Bacillus Calmette Guerin (BCG), to bind and to be internalized by tumor cells without causing patient hypersensitivity, morbidity, and risk of infection. Further, this technology has the potential for use as a targeting agent for the delivery of therapeutics to treat bladder cancer by having this technology formulated into pharmaceutically suitable carriers and administered into the lumen of the bladder. This revolutionizes bladder cancer treatment and can lead to therapeutic innovations in other cancer-based domains such as the treatment of skin and lung cancer.
Coon, B. G., S. Crist, A. M. Gonzalez-Bonet, H. K. Kim, J. Sowa, D. H. Thompson, T. L. Ratliff, and R. C. Aguilar. Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells. International Journal of Cancer, 2012, 131 (3): 591-600. doi: 10.1002/ijc.26413.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
highly recurrent cancers
causing patient hypersensitivity
pharmaceutically suitable carriers
related publications coon
fibronectin attachment protein
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium